Physician profile
Brianna Ayers
NPI 1255953485
$7,490.58
in general payments reported to CMS, 2019-2025
19 companies · $4,015 in 2025
The $4,015 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $1,877 · 2024: $1,450 · 2025: $4,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,457 · Consulting Fee: $2,325 · Education: $489 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,456.75 |
| Consulting Fee | $2,325.00 |
| Education | $489.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,576.19 | 2025 | |
| Janssen Biotech, INC. | $1,513.85 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $716.63 | 2023-2025 | |
| Ucb, INC. | $642.84 | 2023-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $475.65 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $352.71 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $250.35 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $229.59 | 2022-2023 | Otezla |
| Genzyme Corporation | $192.53 | 2023-2025 | |
| Galderma Laboratories, L.P. | $152.01 | 2024-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $133.08 | 2023-2025 | |
| Organon LLC | $84.41 | 2024-2025 | Vtama |
| Incyte Corporation | $41.62 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $33.14 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.95 | 2024 | Spevigo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $21.39 | 2022 | |
| Biowound Solutions, INC. | $18.00 | 2025 | Bio-Connekt |
| Kyowa Kirin, INC. | $17.47 | 2024 | Poteligeo |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.